PURPOSE: To investigate baseline and early apparent diffusion coefficients (ADC) derived from diffusion-weighted imaging (DWI) as a predictor of objective response (OR) and survival in unresectable @entity157 ( @entity157 ) treated with @entity632 drug-eluting bead (DEB) transcatheter arterial chemoembolization. MATERIALS AND METHODS: In a prospective study, 57 @entity1 underwent DEB chemoembolization. Dynamic contrast-enhanced magnetic resonance imaging and DWI were performed at baseline @entity676 months after DEB chemoembolization. OR was evaluated per modified Response Evaluation Criteria In @entity5 (mRECIST) and European Association for the Study of the Liver (EASL) guidelines. Baseline @entity5 that showed OR at 1 and 3 months were compared with nonresponding @entity5 ADCs by two-sample t test and receiver operating characteristic curves. Additionally, ADC changes at 30 days were correlated with OR. Finally, Kaplan-Meier analysis was used to compare survival between @entity1 with lesions demonstrating more restricted baseline diffusion and others. RESULTS: At 1 month, 33 @entity1 (60%) showed OR (21 complete responses and 12 partial responses). At baseline, @entity5 with OR at 1 month showed significantly more restricted diffusion (0.731 * 10(-3) mm(2)/s) compared with others (1.057 * 10(-3) mm(2)/s; P = .031). No difference between response rates at 1 and 3 months according to mRECIST and EASL was observed. For an area under the curve of 0.965, the sensitivity and specificity of predicting objective @entity5 response at 1 month using a baseline @entity157 ADC of 0.83 * 10(-3) mm(2)/s were 91% and 96%, respectively. In addition, @entity1 with lesions with a baseline ADC < 0.83 * 10(-3) mm(2)/s showed prolonged survival compared with others (P < .001). CONCLUSIONS: In unresectable @entity157 , a baseline ADC < 0.83 * 10(-3) mm(2)/s is a predictor of survival and treatment response at 1 and 3 months after DEB chemoembolization with high sensitivity and specificity.

Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable XXXX to @entity632 Drug-Eluting Bead Chemoembolization.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['ADCs of tumors', 'tumor', 'Solid Tumors', 'tumors'] @entity676 :: ('11169', 'Gene') :: ['and 1 and 3'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']
@entity157 :: (MESH:D006528,Disease) :: ['Hepatocellular Carcinoma']
